Literature DB >> 22392125

1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.

Catherine Gozé1, Charlotte Bezzina, Eric Gozé, Valérie Rigau, Thierry Maudelonde, Luc Bauchet, Hugues Duffau.   

Abstract

Mutations at the codon 132 in the isocitrate dehydrogenase 1 (IDH1) gene occur early, with a high frequency, in World Health Organization (WHO) grade II gliomas. We investigated the impact of IDH1 mutations on spontaneous glioma growth rate, known to be an early prognostic factor.The mean tumor diameter was assessed on the first MRI performed at diagnosis and on a second MRI, performed immediately before surgery, in a series of 64 WHO grade II gliomas. The patients did not undergo treatment before surgery. Because of a frequent association, we jointly analyzed the 1p19q co-deletion and IDH1 mutations effects on tumor velocity of diameter expansion (mm/year) during preoperative spontaneous growth period. 1p19q co-deletion had a significant slowing effect (p = 0.0133) on tumor growth estimated at -1.7760 ± 0.711 mm/year (95% CI -3.154, -0.366), whereas IDH1 mutations estimated effect of +0.036 ± 0.833 mm/year (95% CI -1.668; +1.596) was not significant (p = 0.9654). Our results provide first evidence that IDH1 mutations are not significantly involved in tumor growth rate. By contrast, we confirm that 1p19q co-deletion decreases growth velocity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392125     DOI: 10.1007/s11060-012-0831-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

2.  Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.

Authors:  Martin J van den Bent; Leendert H J Looijenga; K Langenberg; Winand Dinjens; Wilfried Graveland; Ludo Uytdewilligen; Peter A Sillevis Smitt; Robert B Jenkins; Johan M Kros
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

3.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

4.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

5.  Dynamic history of low-grade gliomas before and after temozolomide treatment.

Authors:  Damien Ricard; Gentian Kaloshi; Alexandra Amiel-Benouaich; Julie Lejeune; Yannick Marie; Emmanuel Mandonnet; Michèle Kujas; Karima Mokhtari; Sophie Taillibert; Florence Laigle-Donadey; Antoine F Carpentier; Antonio Omuro; Laurent Capelle; Hugues Duffau; Philippe Cornu; Rémy Guillevin; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

6.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

7.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

8.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

9.  Molecular classification of low-grade diffuse gliomas.

Authors:  Young-Ho Kim; Sumihito Nobusawa; Michel Mittelbronn; Werner Paulus; Benjamin Brokinkel; Kathy Keyvani; Ulrich Sure; Karsten Wrede; Yoichi Nakazato; Yuko Tanaka; Anne Vital; Luigi Mariani; Robert Stawski; Takuya Watanabe; Umberto De Girolami; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2010-11-12       Impact factor: 5.770

10.  IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

Authors:  H J Dubbink; W Taal; R van Marion; J M Kros; I van Heuvel; J E Bromberg; B A Zonnenberg; C B L Zonnenberg; T J Postma; J M M Gijtenbeek; W Boogerd; F H Groenendijk; P A E Sillevis Smitt; W N M Dinjens; M J van den Bent
Journal:  Neurology       Date:  2009-11-24       Impact factor: 11.800

View more
  24 in total

1.  Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.

Authors:  Raymond Y Huang; Robert J Young; Benjamin M Ellingson; Harini Veeraraghavan; Wei Wang; Florent Tixier; Hyemin Um; Rasheed Nawaz; Tracy Luks; John Kim; Elizabeth R Gerstner; David Schiff; Katherine B Peters; Ingo K Mellinghoff; Susan M Chang; Timothy F Cloughesy; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

2.  Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.

Authors:  Johan Pallud; Marie Blonski; Emmanuel Mandonnet; Etienne Audureau; Denys Fontaine; Nader Sanai; Luc Bauchet; Philippe Peruzzi; Marc Frénay; Philippe Colin; Rémy Guillevin; Valérie Bernier; Marie-Hélène Baron; Jacques Guyotat; Hugues Duffau; Luc Taillandier; Laurent Capelle
Journal:  Neuro Oncol       Date:  2013-02-07       Impact factor: 12.300

Review 3.  'Low grade glioma': an update for radiologists.

Authors:  Jennifer Larsen; Steve B Wharton; Fiona McKevitt; Charles Romanowski; Caroline Bridgewater; Hesham Zaki; Nigel Hoggard
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

4.  Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Authors:  Catherine Gozé; Marie Blonski; Guillaume Le Maistre; Luc Bauchet; Edouard Dezamis; Philippe Page; Pascale Varlet; Laurent Capelle; Bertrand Devaux; Luc Taillandier; Hugues Duffau; Johan Pallud
Journal:  Neuro Oncol       Date:  2014-05-20       Impact factor: 12.300

5.  Is a prospective trial necessary to suggest a clinical relevance?

Authors:  Johan Pallud; Hugues Duffau
Journal:  Neuro Oncol       Date:  2014-08-05       Impact factor: 12.300

6.  A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers.

Authors:  Dominik Cordier; Catherine Gozé; Sabine Schädelin; Valérie Rigau; Luigi Mariani; Hugues Duffau
Journal:  J Neurooncol       Date:  2014-09-28       Impact factor: 4.130

7.  Regional specificity of 1p/19q co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients.

Authors:  Kai Wang; Yinyan Wang; Xing Fan; Yanong Li; Xing Liu; Jiangfei Wang; Lin Ai; Jianping Dai; Tao Jiang
Journal:  J Neurooncol       Date:  2017-12-11       Impact factor: 4.130

Review 8.  Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Authors:  Michael Weller; Roger Stupp; Monika E Hegi; Martin van den Bent; Joerg C Tonn; Marc Sanson; Wolfgang Wick; Guido Reifenberger
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

9.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

Review 10.  Awake surgery for hemispheric low-grade gliomas: oncological, functional and methodological differences between pediatric and adult populations.

Authors:  Gianluca Trevisi; Thomas Roujeau; Hugues Duffau
Journal:  Childs Nerv Syst       Date:  2016-09-20       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.